Akari Shigemi
About
Akari Shigemi is a scholar working on Infectious Diseases, Pharmacology and Epidemiology.
According to data from OpenAlex, Akari Shigemi has authored 31 papers receiving a total of 652 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 17 papers in Pharmacology and 9 papers in Epidemiology. Recurrent topics in Akari Shigemi's work include Antibiotics Pharmacokinetics and Efficacy (17 papers), Antimicrobial Resistance in Staphylococcus (12 papers) and Pneumonia and Respiratory Infections (6 papers). Akari Shigemi is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (17 papers), Antimicrobial Resistance in Staphylococcus (12 papers) and Pneumonia and Respiratory Infections (6 papers). Akari Shigemi collaborates with scholars based in Japan and Australia. Akari Shigemi's co-authors include Kazuaki Matsumoto, Yasuo Takeda, Kazuro Ikawa, Norifumi Morikawa, Erika Watanabe, Yuta Yokoyama, Yoshihiro Shimodozono, Katsushi Yamada, Yoshio Takesue and Tomoyuki Yamada and has published in prestigious journals such as International Journal of Antimicrobial Agents, Biological and Pharmaceutical Bulletin and American Journal of Infection Control.
In The Last Decade
Akari Shigemi
31 papers receiving 642 citations
Peers
Akari Shigemi
Sean N. Avedissian United States
Maria Amodio-Groton United States
Stefanie Swoboda Germany
Purvi Mehra United States
Monique R. Bidell United States
Denis Bugnon France
Ryan L. Crass United States
J. Nicholas O’Donnell United States
Sara Yankelev United States
Pejman Dehghanyar Austria
Citations per year, relative to Akari Shigemi Akari Shigemi (= 1×)
peers
Sean N. Avedissian
Countries citing papers authored by Akari Shigemi
Since
Specialization
Citations
This map shows the geographic impact of Akari Shigemi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akari Shigemi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akari Shigemi more than expected).
Fields of papers citing papers by Akari Shigemi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Akari Shigemi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akari Shigemi. The network helps show where Akari Shigemi may publish in the future.
Co-authorship network of co-authors of Akari Shigemi
This figure shows the co-authorship network connecting the top 25 collaborators of Akari Shigemi. A scholar is included among the top collaborators of Akari Shigemi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akari Shigemi. Akari Shigemi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Oda, Kazutaka, Kazuaki Matsumoto, Akari Shigemi, et al.. (2024). Validation and development of population pharmacokinetic model of vancomycin using a real-world database from a nationwide free web application. Journal of Infection and Chemotherapy. 30(12). 1244–1251.
2.
Oda, Kazutaka, Tomoyuki Yamada, Kazuaki Matsumoto, et al.. (2023). Model‐informed precision dosing of vancomycin for rapid achievement of target area under the concentration‐time curve: A simulation study. Clinical and Translational Science. 16(11). 2265–2275.
3.
Oda, Kazutaka, Tomoyuki Yamada, Kazuaki Matsumoto, et al.. (2023). Model‐informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration‐time curve: A simulation study. Clinical and Translational Science. 16(4). 704–713.
4.
Kawamura, Hideki, Nao Murata, Akari Shigemi, et al.. (2023). Enhanced measures, including PCR-based screening and syndromic surveillance for nosocomial outbreaks of the COVID-19 Omicron variant, using descriptive epidemiology and whole-genome sequencing in a Japanese tertiary care hospital. Journal of Infection and Chemotherapy. 30(2). 104–110.
5.
Shigemi, Akari, Kazutaka Oda, Victor Tuan Giam Chuang, et al.. (2023). A cohort study of the risk factors and the target AUC to avoid vancomycin-associated acute kidney injury in pediatric patients. Journal of Infection and Chemotherapy. 30(4). 323–328.
6.
Kawamura, Hideki, et al.. (2023). 1450. Managing a Multidrug-resistant Acinetobacter baumannii Outbreak in the ICU: A Successful KAIZEN Program Using Process Indicators for Antimicrobial Stewardship, Hand Hygiene, and Standardization. Open Forum Infectious Diseases. 10(Supplement_2).
7.
Terazono, Hideyuki, Akari Shigemi, Hiroaki Nishimura, et al.. (2022). Case Reports: Increase in Blood Concentration of Tacrolimus in Patients with Renal Transplantation under COVID-19 Treatment. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 48(2). 106–111.
8.
Kimura, Toshimi, Yukihiro Hamada, Takashi Niwa, et al.. (2021). Candidates for area under the concentration–time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients. Journal of Global Antimicrobial Resistance. 27. 12–19.
9.
Watanabe, Erika, Kazuaki Matsumoto, Kazuro Ikawa, et al.. (2020). Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model. Journal of Global Antimicrobial Resistance. 24. 83–87.
10.
Takeda, Yasuo, Kazuaki Matsumoto, Erika Watanabe, et al.. (2016). Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections. Clinical Pharmacology Advances and Applications. 8. 15–15.
11.
Kawamura, Hideki, Kazuaki Matsumoto, Akari Shigemi, et al.. (2015). A bundle that includes active surveillance, contact precaution for carriers, and cefazolin-based antimicrobial prophylaxis prevents methicillin-resistant Staphylococcus aureus infections in clean orthopedic surgery. American Journal of Infection Control. 44(2). 210–214.
12.
Matsumoto, Kazuaki, Akari Shigemi, Erika Watanabe, et al.. (2014). Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. International Journal of Antimicrobial Agents. 44(3). 242–247.
13.
Yokoyama, Yuta, Kazuaki Matsumoto, Kazuro Ikawa, et al.. (2014). Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models. International Journal of Antimicrobial Agents. 43(6). 547–552.
14.
Kawamura, Hideki, et al.. (2013). Analysis of Important Areas Identified by Infection Control Team Rounds at A University Hospital. Japanese Journal of Infection Prevention and Control. 28(1). 25–28.
15.
Shigemi, Akari, Kazuaki Matsumoto, Kazuro Ikawa, et al.. (2011). Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia. International Journal of Antimicrobial Agents. 38(5). 417–420.
16.
Matsumoto, Kazuaki, Akari Shigemi, Yoshihiro Shimodozono, et al.. (2011). Reduction in the incidence of MRSA with use of alcohol-based hand rub solutions and gloves. Journal of Infection and Chemotherapy. 18(2). 269–271.
17.
Matsumoto, Kazuaki, Kazuro Ikawa, Akari Shigemi, et al.. (2010). Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. International Journal of Antimicrobial Agents. 36(2). 179–181.
18.
Matsumoto, Kazuaki, et al.. (2010). An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication. Journal of Infection and Chemotherapy. 17(2). 297–300.
19.
Shigemi, Akari, Kazuaki Matsumoto, Yoshihiro Shimodozono, et al.. (2009). Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa. International Journal of Antimicrobial Agents. 34(6). 589–591.
20.
Ogata, Atsuko, et al.. (2008). A Case Report of a Phenytoin Toxic Stroke Patient with Genetic CYP2C19 Polymorphism. The Japanese Journal of Rehabilitation Medicine. 45(9). 617–622.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sean N. Avedissian Breakdown of academic impact, for papers by Maria Amodio-Groton Breakdown of academic impact, for papers by Stefanie Swoboda Breakdown of academic impact, for papers by Purvi Mehra Breakdown of academic impact, for papers by Monique R. Bidell Breakdown of academic impact, for papers by Denis Bugnon Breakdown of academic impact, for papers by Ryan L. Crass Breakdown of academic impact, for papers by J. Nicholas O’Donnell Breakdown of academic impact, for papers by Sara Yankelev Breakdown of academic impact, for papers by Pejman Dehghanyar